Rhone-Poulenc Rorer Intal HFA
Executive Summary
Non-chlorofluorocarbon formulation of asthma therapy cromolyn is "approvable" at FDA May 14. RPR is responding to chemistry and manufacturing issues raised by FDA. The NDA for the hydrofluoralkane-propelled product was submitted on May 15, 1998